Upcoming event
Masterclass on Focal therapy for localised prostate cancer
Back

Tag: Androgen deprivation therapy

Darolutamide with androgen deprivation therapy and definitive or salvage locoregional radiation therapyfor localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 trial (DASL-HiCaP; ANZUP1801)

Perioperative apalutamide plus androgen-deprivation therapy with radical prostatectomy plus pelvic lymph node dissection (RP + PLND) vs RP + PLND alone in patients with high-risk localized or locally advanced prostate cancer: PROTEUS substudy

Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC)